Everolimus in clinical practice. Review of German non-interventional study of everolimus in metastatic renal cell cancer after failure of initial tyrosine kinase inhibitor therapy
Journal Title: OncoReview - Year 2013, Vol 3, Issue 3
Abstract
Everolimus is a standard for treatment of anti-vascular endothelial growth factor (VEGF)-refractory patients with metastatic renal cell carcinoma (mRCC). A German study documented mRCC patient treated everolimus from 79 sites. Results from German study were better then RECORD-1 study – the median time to progression was 7 months versus the median progression free survival was 4.9 months but results from non-interventional study should be treated with reserve. Tolerance of everolimus was good. Pneumonitis was reported as an AE for only 3% patient, in RECORD-1 study in 14%. Results from German study and strategy of sequential treatment were discussed (results from studies INORSECT, AXIS, RECORD-3).
Authors and Affiliations
Paweł Nurzyński, Andrzej Deptała
Późny nawrót przewlekłej białaczki szpikowej po alogenicznym przeszczepieniu komórek macierzystych - opis przypadku
Przewlekła białaczka szpikowa obecnie w większości przypadków jest chorobą dobrze poddającą leczeniu inhibitorami kinazy tyrozynowej. Nadal jednak jedyną procedurą leczniczą dającą możliwość wyleczenia jest aloprzeszczep...
Role of recombinant human erythropoietin in the treatment of cancer-related anaemia
Anaemia is one of the most frequently diagnosed complications in cancer patients and also occurs during the course of cancer treatment. The condition can be observed in as many as 60–70% of patients who receive chemother...
Tyrosine kinase inhibitors in hematologic malignancy: should we be concerned?
Terapie celowane wysoko zróżnicowanych guzów neuroendokrynnych
Guzy neuroendokrynne (NETs, neuroendocrine tumors) stanowią heterogenną grupę nowotworów o różnej biologii i rokowaniu. Terapia zaawansowanych raków neuroendokrynnych jest ograniczona. Leczenie chirurgiczne, bezpośrednia...
Long-term survival of a young patient after multi-disciplinary treatment of initially inoperable stomach cancer with metastases to the liver and visceral lymph node
This paper reports on a 5-year survival of a 30-year-old male patient initially diagnosed with inoperable stomach cancer with metastases to the liver and the visceral lymph node. The systemic treatment regimen (8 cycles...